Switch theme
Sign up to access all valuation multiples
Mycenax Biotech Inc is a Taiwan-based biopharmaceutical company. It is engaged in the development and manufacture of biopharmaceutical products, specializing in mammalian and microbial cell-derived biologics. The company provides services for program evaluation/confirmation, cell line development, and construction, process development technology platforms, drug characterization analysis, the establishment of testing methods, and drug production in accordance with PIC/S GMP manufacturing standards.
2001
337
LTM Revenue n/a
LTM EBITDA n/a
$213M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Mycenax Biotech has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Mycenax Biotech achieved revenue of $20.7M and an EBITDA of -$4.1M.
Mycenax Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Mycenax Biotech valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $19.7M | $20.7M | XXX | XXX | XXX |
| Gross Profit | -$3.4M | -$11.3M | XXX | XXX | XXX |
| Gross Margin | -17% | -55% | XXX | XXX | XXX |
| EBITDA | -$10.3M | -$4.1M | XXX | XXX | XXX |
| EBITDA Margin | -52% | -20% | XXX | XXX | XXX |
| Net Profit | -$13.7M | -$20.6M | XXX | XXX | XXX |
| Net Margin | -70% | -100% | XXX | XXX | XXX |
| Net Debt | n/a | $4.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Mycenax Biotech's stock price is TWD 31 (or $1).
Mycenax Biotech has current market cap of TWD 6.5B (or $195M), and EV of TWD 7.1B (or $213M).
See Mycenax Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $213M | $195M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Mycenax Biotech has market cap of $195M and EV of $213M.
Mycenax Biotech's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Mycenax Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Mycenax Biotech and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $213M | XXX | XXX | XXX |
| EV/Revenue | 10.3x | XXX | XXX | XXX |
| EV/EBITDA | -51.8x | XXX | XXX | XXX |
| P/E | -13.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -13.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMycenax Biotech's NTM/LTM revenue growth is n/a
Mycenax Biotech's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $20K for the same period.
Over next 12 months, Mycenax Biotech's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Mycenax Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Mycenax Biotech and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -20% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -60% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $20K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 13% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 11% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 32% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mycenax Biotech acquired XXX companies to date.
Last acquisition by Mycenax Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Mycenax Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Mycenax Biotech founded? | Mycenax Biotech was founded in 2001. |
| Where is Mycenax Biotech headquartered? | Mycenax Biotech is headquartered in Taiwan. |
| How many employees does Mycenax Biotech have? | As of today, Mycenax Biotech has 337 employees. |
| Is Mycenax Biotech publicy listed? | Yes, Mycenax Biotech is a public company listed on ROCO. |
| What is the stock symbol of Mycenax Biotech? | Mycenax Biotech trades under 4726 ticker. |
| When did Mycenax Biotech go public? | Mycenax Biotech went public in 2013. |
| Who are competitors of Mycenax Biotech? | Similar companies to Mycenax Biotech include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Mycenax Biotech? | Mycenax Biotech's current market cap is $195M |
| What is the current revenue growth of Mycenax Biotech? | Mycenax Biotech revenue growth between 2023 and 2024 was 5%. |
| Is Mycenax Biotech profitable? | Yes, Mycenax Biotech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
